Chargement en cours...
Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
AIM: That clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo...
Enregistré dans:
| Publié dans: | PLoS One |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7205241/ https://ncbi.nlm.nih.gov/pubmed/32379763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0232240 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|